# Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females

> **NCT02740777** · PHASE2 · COMPLETED · sponsor: **Shanghai Zerun Biotechnology Co.,Ltd** · enrollment: 900 (actual)

## Conditions studied

- Human Papillomavirus
- Cervical Intraepithelial Neoplasia
- Persistent Infection

## Interventions

- **BIOLOGICAL:** HPV-16/18 vaccine

## Key facts

- **NCT ID:** NCT02740777
- **Lead sponsor:** Shanghai Zerun Biotechnology Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-11
- **Final completion:** 2019-07
- **Target enrollment:** 900 (ACTUAL)
- **Last updated:** 2023-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02740777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02740777, "Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02740777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*